ZURA BIO LIMITED Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ZURA BIO LIMITED (ZURA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 18.86 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 16.22M shares, a 2.87% decline year-over-year.
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 16.70M shares, a 29.56% decline year-over-year.
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 23.71M shares, a 55.49% increase year-over-year.
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 15.25M shares.
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 14.93M shares, a 11.36% increase from fiscal 2024.
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 13.41M shares, a 40.78% decline from fiscal 2023.
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 22.64M shares, a 62.98% increase from fiscal 2022.
- ZURA BIO LIMITED antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 13.89M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 7 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 10 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 18.86M shares 10-Q · filed 2026-08-11 | |||||||||
| 2026-03-31 | 16.22M shares 10-Q · filed 2026-05-07 | |||||||||
| 2025-12-31 | 14.93M shares 10-K · filed 2026-03-19 | |||||||||
| 2025-09-30 | 17.30M shares 10-Q · filed 2025-11-13 | |||||||||
| 2025-06-30 | 17.56M shares 10-Q · filed 2026-08-11 | |||||||||
| 2025-03-31 | 16.70M shares 10-Q · filed 2026-05-07 | |||||||||
| 2024-12-31 | 13.41M shares 10-K · filed 2026-03-19 | |||||||||
| 2024-09-30 | 12.74M shares 10-Q · filed 2025-11-13 | |||||||||
| 2024-06-30 | 26.29M shares 10-Q · filed 2025-08-14 | |||||||||
| 2024-03-31 | 23.71M shares 10-Q · filed 2025-05-08 | |||||||||
| 2023-12-31 | 22.64M shares 10-K · filed 2025-03-25 | |||||||||
| 2023-09-30 | 22.70M shares 10-Q · filed 2024-11-07 | |||||||||
| 2023-06-30 | 21.89M shares 10-Q · filed 2024-08-13 | |||||||||
| 2023-03-31 | 15.25M shares 10-Q · filed 2024-05-09 | |||||||||
| 2022-12-31 | 13.89M shares 10-K · filed 2024-03-28 | 450.00K shares 10-K · filed 2023-03-28 | ||||||||
| 2022-09-30 | 13.89M shares 10-Q · filed 2023-11-13 | |||||||||
| 2022-06-30 | 13.89M shares 10-Q · filed 2023-08-14 | |||||||||
| 2022-03-31 | 13.51M shares 10-Q · filed 2023-05-12 | |||||||||
| 2021-12-31 | 450.00K shares 10-K · filed 2022-04-11 | |||||||||
| 2021-09-30 | 450.00K shares 10-Q · filed 2022-11-14 | |||||||||
| 2021-06-30 | 450.00K shares 10-Q · filed 2022-08-12 | |||||||||
| 2021-03-31 | 450.00K shares 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |